 |
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about BiCNU.
No reviews have yet been submitted. Be the first to review this drug.
Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and...
Cell Therapeutics, Inc. ("CTI") announced today that it has voluntarily withdrawn its New Drug Application ("NDA") for Pixuvri (pixantrone) for the...
CAMBRIDGE, Mass., January 23, 2012–Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced...
Jan 13, 2012 - Seattle Genetics, Inc. today announced updates to the U.S. Prescribing Information (PI) for Adcetris (brentuximab vedotin). The revised PI...
Cell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee...
Looking for answers? Ask a question or go join the BiCNU support group to connect with others who have similar interests.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2012 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
